1. Home
  2. FKWL vs VERU Comparison

FKWL vs VERU Comparison

Compare FKWL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Wireless Corp.

FKWL

Franklin Wireless Corp.

HOLD

Current Price

$3.74

Market Cap

44.7M

Sector

Utilities

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.26

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FKWL
VERU
Founded
1981
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
44.7M
40.9M
IPO Year
1997
1996

Fundamental Metrics

Financial Performance
Metric
FKWL
VERU
Price
$3.74
$2.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$22.50
AVG Volume (30 Days)
6.0K
51.7K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
1.10%
N/A
EPS Growth
94.12
N/A
EPS
0.10
N/A
Revenue
$46,086,901.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.14
N/A
P/E Ratio
$37.30
N/A
Revenue Growth
49.65
N/A
52 Week Low
$3.52
$0.36
52 Week High
$5.48
$4.59

Technical Indicators

Market Signals
Indicator
FKWL
VERU
Relative Strength Index (RSI) 52.39 44.64
Support Level $3.73 $2.13
Resistance Level $3.94 $2.70
Average True Range (ATR) 0.07 0.09
MACD 0.01 -0.01
Stochastic Oscillator 77.27 25.93

Price Performance

Historical Comparison
FKWL
VERU

About FKWL Franklin Wireless Corp.

Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: